BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16995354)

  • 21. [New data on hypoglycemia risk and beta cell function].
    MMW Fortschr Med; 2007 Nov; 149(44):57. PubMed ID: 18078171
    [No Abstract]   [Full Text] [Related]  

  • 22. [Advantages of fast-acting insulin analogs: preprandial greater HbA1c lowering -- postprandial lower weight].
    MMW Fortschr Med; 2005 Aug; 147(33-34):45. PubMed ID: 16138637
    [No Abstract]   [Full Text] [Related]  

  • 23. Is basal insulin always the first choice for initiation of insulin therapy in type 2 diabetic patients?
    Mannucci E; Monami M; Masotti G; Marchionni N
    Exp Clin Endocrinol Diabetes; 2007 May; 115(5):339-40. PubMed ID: 17516300
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of fasting capillary glucose variability between insulin glargine and NPH.
    Mu P; Lu H; Zhang G; Chen Y; Fu J; Wang M; Shu J; Zeng L
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e4-7. PubMed ID: 20970870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
    Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
    Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
    MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
    [No Abstract]   [Full Text] [Related]  

  • 27. [Certain beginning of insulin therapy: yes, we can, but...].
    Rohrer A
    Praxis (Bern 1994); 2009 Mar; 98(6):301. PubMed ID: 19338117
    [No Abstract]   [Full Text] [Related]  

  • 28. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].
    Spirk D; Lareida J; Scheidegger K; Diem P
    Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Supplemental insulin therapy of type 2 diabetes follows the example of nature. Replace what the patient lacks].
    MMW Fortschr Med; 2004 May; 146(22):47. PubMed ID: 15373112
    [No Abstract]   [Full Text] [Related]  

  • 32. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.
    Kato T; Tokubuchi I; Muraishi K; Sato S; Kato T; Hara K; Tanaka K; Kaku H; Tajiri Y; Yamada K
    Diabetes Res Clin Pract; 2010 Dec; 90(3):e64-6. PubMed ID: 20850885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [When oral therapy of type 2 diabetes fails--basal insulin is more effective than change in life style (interview by Dr. Thomas Meissner)].
    MMW Fortschr Med; 2008 Aug; 150(32-35):28-9. PubMed ID: 19006878
    [No Abstract]   [Full Text] [Related]  

  • 36. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.
    Wolffenbuttel BH; Klaff LJ; Bhushan R; Fahrbach JL; Jiang H; Martin S
    Diabet Med; 2009 Nov; 26(11):1147-55. PubMed ID: 19929994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.
    Sakharova OV; Lleva RR; Dziura JD; Spollett GR; Howell SK; Beisswenger PJ; Inzucchi SE
    J Diabetes Complications; 2012; 26(4):333-8. PubMed ID: 22541894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Learning from ORIGIN.
    Bloomgarden ZT
    J Diabetes; 2012 Sep; 4(3):191-2. PubMed ID: 22716648
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
    Blonde L; Baron MA; Zhou R; Banerji MA
    Postgrad Med; 2014 May; 126(3):172-89. PubMed ID: 24918802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.